Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer and colorectal cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint FFPE as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology, and TargetPrint, a breast cancer ER/PR/HER2 expression assay. These tests can help physicians assess a patient's individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods.
Missing: Agendia's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Agendia's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Agendia
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Agendia in 2 CB Insights research briefs, most recently on Dec 16, 2020.
Expert Collections containing Agendia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Agendia is included in 7 Expert Collections, including Women's Health & Wellness.
Women's Health & Wellness
Startups focused on providing products and services catering to women's health and wellbeing.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Agendia has filed 1 patent.
Experimental cancer drugs, Transcription factors, Breast cancer, Monoclonal antibodies for tumors, Oncology
Experimental cancer drugs, Transcription factors, Breast cancer, Monoclonal antibodies for tumors, Oncology
Latest Agendia News
Nov 16, 2022
The LESS study will evaluate reduced endocrine therapy for HR+/HER2- patients with MammaPrint® Ultra Low tumors to improve quality of life without compromising outcomes Study strengthens Agendia’s growing global footprint in breast cancer to inform personalized treatment planning worldwide November 16, 2022 09:00 AM Eastern Standard Time IRVINE, Calif. & AMSTERDAM--( BUSINESS WIRE )-- Agendia, Inc. , a commercial-stage company focused on assessing an individual tumor’s risk of metastasis and the molecular subtyping reasons for its growth, today announced the first patient has enrolled in the LESS clinical trial, sponsored by Unicancer with the institutional support of Agendia. In an effort to improve outcomes while preserving quality of life for early breast cancer patients, the study is designed to safely discontinue adjuvant endocrine therapy after two years for tumors with a MammaPrint Ultra Low result in post-menopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study aims to enroll 696 patients via 45 sites within the French breast cancer intergroup Unicancer (UCBG) by October 2024. “We are excited to identify early breast cancer tumors and further investigate the ability to reduce endocrine therapy duration, in an effort to minimize significant and varying side effects, while maintaining high survival rates,” said Fabrice André, MD, PhD, Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France and Co-coordinating Investigator of the study. Elise Deluche, MD, Deputy Head of Department at Centre Hospitalier Universitaire de Limoges and Co-coordinating Investigator of the study, added, “Enabling personalized treatments to prevent over- and undertreatment in breast cancer care could give women freedom from intensive long-term treatment regimens that may not increase their chance of cure.” Previous studies have shown patients with HR+/HER2- breast cancer with a MammaPrint Ultra Low result can have an excellent prognosis at 20 years with reduced endocrine therapy. “The LESS study is an important addition to Agendia leading the field in uncovering robust insights for patients and their providers to tailor treatments unique to every tumor,” said William Audeh, MD, Chief Medical Officer at Agendia. “Through our partnership with Unicancer, we are expanding knowledge on the complexity of breast cancer and enabling further personalized treatments in cancer care.” Agendia’s singular focus on breast cancer facilitates continued investment in global research to unravel the intricacies of precision medicine and drive personalized treatment planning for women with breast cancer. This study reinforces Agendia’s commitment to practice changing research that will aid decision-making, aimed at improving outcomes. About Agendia Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey. MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of the biology underlying an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com . About Unicancer Unicancer is the only French hospital network 100% dedicated to the fight against cancer and the only national hospital federation dedicated to cancer. It brings together the 18 French Cancer Comprehensive Centres (FCCCs), private not-profit health establishments, spread over 20 hospital sites in France, as well as 2 affiliated establishments. The FCCCs take care of nearly 540,000 patients per year (in short-stay, HAD and outpatient procedures). Unicancer is also the leading academic promoter of clinical trials in oncology, on a European scale, with 109 active clinical trials promoted, 20,000 patients included, 83,000 patients registered in the ESME database. Recognised as a leader in research in France, the Unicancer network enjoys a worldwide reputation with the production of one third of French publications of international importance in oncology (source: bibliometric study/Thomson Reuters). In total, more than 700 clinical trials (inclusions or follow-ups) are promoted in 2021 by the Unicancer network, more than 16% of CLCC patients are included in clinical trials and more than half of the PHRCs devolved to FCCCs. The 18 FCCCs and the Unicancer R&D department are ISO 9001 certified. Contacts
Agendia Web Traffic
Agendia Frequently Asked Questions (FAQ)
When was Agendia founded?
Agendia was founded in 2003.
Where is Agendia's headquarters?
Agendia's headquarters is located at Amsterdam.
What is Agendia's latest funding round?
Agendia's latest funding round is Unattributed.
How much did Agendia raise?
Agendia raised a total of $163.8M.
Who are the investors of Agendia?
Investors of Agendia include Athyrium Capital Management, Horizon 2020, Gilde Healthcare, Van Herk, Breedinvest and 8 more.
Who are Agendia's competitors?
Competitors of Agendia include OncoGenomX and 1 more.
Compare Agendia to Competitors
euroCAT improves cancer treatment and research by using a new, advanced computer network for clinical research and decision-supporting software. The company's advanced computer network rapidly identifies patients for clinical trials and automates many of the standard processes. The company develops a shared database of medical characteristics of cancer patients, tumors, and treatments. It was founded in 2010 and is based in Maastricht, Netherlands.
Auspex provides artificial intelligence-based advanced cancer diagnostics services intended to improve the quality of cancer care. The company's machine learning algorithm analyzes the genomic information of patients' tumor sample and accurately assess the risk of recurrence and drug efficacy, enabling the oncologists and patients to make the optimal data-driven decisions and personalize the treatment plan.
OncoGenomX provides a predictive software product that helps in diagnosing breast cancer. The solution is meant for use by laboratories and physicians. It was founded in 2020 and is based in Allschwil, Switzerland.
Exact Sciences (NASDAQ: EXAS) is an applied genomics company with a mission to contribute to the eradication of common cancers by applying advances in the field of genomics to facilitate the early detection of diseases. The company was founded in 1995 and is based in Madison, Wisconsin.
Genomic Health is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.
Myriad Genetics is a molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad offers an array of genetic tests, prognostic tests and personalized medicine tests to help healthcare providers assess a patient's increased cancer risk, disease aggressiveness and optimize efficacy of chemotherapy. Myriad's testing products can provide healthcare providers with information to help make medical management decisions to reduce cancer risk and help make sure specific treatments are tailored for each individual patient. It was founded in 1991 and is based in Salt Lake City, Utah.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.